The Emerging Role of PARP Inhibitors in the Treatment of Prostate Cancer
( Prostate Cancer - Leading-edge Diagnostic Procedures and Treatments )
Publication series ： Prostate Cancer - Leading-edge Diagnostic Procedures and Treatments
Author： Jue Wang Brent B. Freeman and Paul Mathew
Publisher： IntechOpen
Publication year： 2016
E-ISBN: INT6161963283
P-ISBN(Paperback): 9789535126447
P-ISBN(Hardback): 9789535126454
Subject： R4 Clinical Medicine;R6 Surgery
Keyword： 外科学,临床医学
Language： ENG
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
The Emerging Role of PARP Inhibitors in the Treatment of Prostate Cancer
Description
Poly (ADPribose) polymerase (PARP) is a critical DNA repair enzyme involved in DNA single-strand break repair through the base excision repair pathway. PARP inhibitors have been shown to sensitize tumors to DNA-damaging agents and selectively kill homologous recombination repair-defective cancers, such as those arising in BRCA1 and BRCA2 mutation carriers. In addition to its well-documented role in DNA damage repair (DDR), emerging evidence has indicated that PARP1 plays an important role in mediating the transcriptional activities of androgen receptor (AR) and ETS gene rearrangement in prostate cancer. Preclinical and clinical research suggested that the activity of PARP inhibitors is not limited to those with BRCA mutations. PARP inhibitors may have activity in cancers deficient in other DNA repair genes or signaling pathways that mitigate DNA repair.
Chapter